SUCHTUTORIUM ANZEIGENSuch-Tutorium anzeigen
(Benötigt Flash, öffnet sich in neuem Fenster) Show Tutorial VideoSuch-Tutorium anzeigen
(Benötigt Flash, öffnet sich in neuem Fenster)
Produktdetails

anti-CEACAM5 (CEA, CD66e) Antikörper

Übersicht

Bild für anti-CEACAM5 (CEA, CD66e) Antikörper
Antigen: CEACAM5 (CEA, CD66e)
Klonalität: Monoklonal (26-3-13)
Applikation: Flow Cytometry (FACS), Cell-ELISA (cELISA), Immunohistochemistry (IHC), ELISA, Western Blotting (WB)
Reaktivität: Human
Wirt: Mouse
9 Publikationen vorhanden 9 Publikationen vorhanden
Menge: 100 ug (1mg/ml)
Preis: 250,00 €   (Zzgl. Versandkosten und MWSt)
Bestellnummer: ABIN108727
Verfügbarkeit: Versandbereit innerhalb von 1 bis 2 Werktagen
Bestellhinweis Bestellhinweis
In den Warenkorb

Auf dieser Seite

Produktbeschreibung
Anwendungen
Publikationen
Bilder
Verwandte Produkte
Protokolle

Kundenservice

Technische Anfrage stellen
Produktdetails an Kollegen senden
Datenblatt herunterladen

Produktbeschreibung  » anti-CEACAM5 (CEA, CD66e) Antikörper

zurück nach oben ^


Antigen CEACAM5 (CEA, CD66e)
Immunogen Immunisation with extracted protein of CEACAM5
Reaktivität Human
Klonalität Monoklonal
Format Purified
Isotyp IgG1 »Passende Sekundärantikörper
Beschreibung CEACAM5 (CEA-related cell adhesion molecule 5, CEA) belongs to the carcinoembryonic antigen (CEA) gene family (5). It encodes a glycosyl phosphatidylinositol (GPI)- linked glycoprotein with a Mr of 180,000-200,000 which is most strongly expressed on epithelial cells of the fetal and adult colon and to a minor extent on epithelial cells of the stomach and sweat glands, squamous epithelial cell of the tongue, esophagus and cervix. CEACAM5 is used as a tumor marker for early detection of recurrent disease due its expression in adenocarcinomas of the colon, lung, breast, stomach and pancreas and in mucinous ovarian carcinomas (5). Like all members of the CEACAM family, it consists of a single N domain, with structural homology to the immunoglobulin variable domains, followed by six immunoglobulin constant-like A (A1, A2, A3) and B domains (B1, B2, B3).
Klon 26-3-13
Wirt Mouse
Spezifität Anti-human CEACAM5 (CEA, CD66e)

Anwendungen  » anti-CEACAM5 (CEA, CD66e) Antikörper

zurück nach oben ^


Applikation Flow Cytometry (FACS), Cell-ELISA (cELISA), Immunohistochemistry (IHC), ELISA, Western Blotting (WB)
» Hier finden Sie 9 Protokolle zu den gelisteten Anwendungen
Applikationshinweise Flow cytometry: 1.2 ug/10^6 cells. ELISA: 1:200 - 1:400 CELISA: 1:200. Western blot: 4ug/ml. Immunohistology: 1-2 ug/10^6 cells (on cryosections)
Konzentration 1mg/ml
Reinigung Protein G
Buffer Phosphate buffered saline, pH 7.2
Lagerung Short term: 2°C - 8°C. Long term: -20°C (avoid repeated freezing and thawing)
Forschungsgebiet Rezeptoren, Krebs, Rezeptoren, Zell-/Gewebemarker, Krebs
Beschränkungen Nur für Forschungszwecke einsetzbar

Publikationen  » anti-CEACAM5 (CEA, CD66e) Antikörper

zurück nach oben ^


Publikationen Strobel, Strobel, Bross et al.: "Effects of human bone marrow stroma on the growth of human tumor cells." In: Cancer research , Vol. 49, Issue 4, pp. 1001-7, 1989 (PubMed)

Grunert, AbuHarfeil, Schwarz et al.: "Two CEA and three NCA species, although distinguishable by monoclonal antibodies, have nearly identical peptide patterns." In: International journal of cancer. Journal international du cancer , Vol. 36, Issue 3, pp. 357-62, 1985 (PubMed)

Thompson, Moessinger, Reichardt et al.: "A polymerase-chain-reaction assay for the specific identification of transcripts encoded by individual carcinoembryonic antigen (CEA)-gene-family members." In: International journal of cancer. Journal international du cancer , Vol. 55, Issue 2, pp. 311-9, 1993 (PubMed)

Krop-Watorek, Laskowska, Salwa et al.: "CEA-related proteins on human urothelial cell lines of different transformation grades." In: Cancer letters , Vol. 139, Issue 1, pp. 15-22, 1999 (PubMed)

Schoelzel, Zimmermann, Schwarzkopf et al.: "Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas." In: The American journal of pathology , Vol. 156, Issue 2, pp. 595-605, 2000 (PubMed)

Baczy?ska, Wietrzyk, Madej et al.: "The tumorigenic potential of human CX-1 colon adenocarcinoma cells depends on carcinoembryonic antigen (CEACAM5) expression." In: Cellular & molecular biology letters , Vol. 8, Issue 2, pp. 471-86, 2003 (PubMed)

Schmitter, Agerer, Peterson et al.: "Granulocyte CEACAM3 is a phagocytic receptor of the innate immune system that mediates recognition and elimination of human-specific pathogens." In: The Journal of experimental medicine , Vol. 199, Issue 1, pp. 35-46, 2004 (PubMed)

Kammerer, Riesenberg, Weiler et al.: "The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma." In: The Journal of pathology , Vol. 204, Issue 3, pp. 258-67, 2004 (PubMed)

Noeckel, van den Engel, Winter et al.: "Characterization of gastric adenocarcinoma cell lines established from CEA424/SV40 T antigen-transgenic mice with or without a human CEA transgene." In: BMC cancer , Vol. 6, pp. 57, 2006 (PubMed)